Description
The ARPA‑H SBIR/STTR Broad Agency Announcement (BAA) seeks innovative, health‑focused research and development proposals from eligible U.S. small businesses. Eight topics are open, covering fertility diagnostics, bio‑adhesives, universal toxin‑removal platforms, non‑surgical endometriosis therapies, lineage commercialization, autoimmune disease diagnostics, and a virtual brain for neurosurgical robotics. Proposers submit a 4‑page Solution Summary (5 pages for Fast‑Track) by the Stage 1 deadline, then, if encouraged, a full Stage 2 proposal with technical presentations, cost breakdowns, and key‑personnel worksheets. Funding ceilings are roughly $600 k for Phase I and $3.5 M for Phase II per topic, with Phase I lasting up to 12 months and Phase II up to 36 months. The solicitation is set‑aside for SBA‑qualified small businesses and requires compliance with SBIR/STTR data‑rights, Section 508 accessibility, and human‑subjects/animal‑care regulations.
• Eligible U.S. small businesses (≤500 employees) can submit up to nine SBIR/STTR proposals per fiscal year.
• Eight research topics address high‑impact health challenges, each with defined technical objectives and anticipated budgets.
• Phase I (≤12 mo, $600 k) proves feasibility; Phase II (24‑36 mo, $3.5 M) advances prototypes toward commercialization.
• Fast‑Track combines Phase I and II in a single award; a separate commercial‑plan page is required.
Attached files
Contact
Business Innovation Division(Business Innovation Division)